JOAN M KITAGWA-VISITING RESIDENT IN CLINICAL ONCOLOGY AND NUCLEAR MEDICINE, FACULTY OF MEDICINE, ALEXANDRIA UNIVERSITY | ||||
| ALEXMED ePosters | ||||
| Article 116, Volume 3, Issue 2, June 2021, Page 47-48 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2021.77394.1164 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Joan M Kitagwa 
| ||||
| Department of clinical oncology and nuclear medicine, Faculty of medicine, Alexandria University | ||||
| Abstract | ||||
| Every year, approximately 100,000 people worldwide are diagnosed as having diffuse gliomas. Glioblastoma multiform (GBM), the most lethal glioma, accounts for 75% of all diffuse glioma diagnoses and has a median overall survival of 14–17 months. The standard initial approach for GBM is maximal safe surgical resection, which is followed by radiotherapy (RT) (60 Gray [Gy] over 6 weeks) with concomitant daily Temozolomide (TMZ) and a further 6 cycles of maintenance TMZ. Extending TMZ beyond 6 cycles has been shown to delay disease progression in some studies. Some guidelines suggest that this strategy is to be considered in patients with partial response or with continuing radiological improvement at the end of the 6th cycle. The residual disease is however expected in all patients with GBM and thus, it is hoped that additional cycles of TMZ will delay recurrence. AIM OF THE WORK This is a retrospective study to assess the impact of extended Temozolomide (TMZ) maintenance therapy (more than 6 cycles) in comparison with standard 6 cycles of TMZ maintenance therapy on overall survival (OS) and progression-free survival (PFS) in glioblastoma multiforme (GBM) patients. | ||||
| Keywords | ||||
| Glioblastoma multiform (GBM); Temozolomide (TMZ); Extending TMZ beyond 6 | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 149 |
||||
